AEterna Zentaris to Announce Third Quarter 2009 Financial and Operating Results on November 11, 2009
More News related to AEZ
- AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
- American Oil & Gas Updates Fetter Field Niobrara Re-Completion Program
- AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology
- Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
- AEterna Zentaris Reports Third Quarter 2009 Financial and Operating Results
More News related to AEZS
- Emerging Stock Report Initiates Independent Research Coverage on AEterna Zentaris Inc.
- Morning Movers 11/24: IWA, SEED, FEED, AEZS Higher; WH, ORS, ABIO, GRO, LONG Lower
- AEterna Zentaris (AEZS) Announces Phase 2 Results of AEZS-108 Endometrial Cancer Treatment
- AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
- AEterna Zentaris (AEZS) Reports That Perifosine Partner Keryx Biopharma (KERX) Will Prersent Data from Phase 1/2 at 51st ASH Meeting
More News related to Press Releases
- Keefe, Bruyette & Woods Downgrades First State Bancorporation (FSNM) to Market Perform
- Keefe, Bruyette & Woods Downgrades R&G Financial (RGFC) to Market Perform
QUEBEC CITY, Nov. 4 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce its third quarter 2009 financial and operating results before market open on Wednesday, November 11, 2009. The Company will host a conference call and webcast to discuss these results later that same day at 10:00 a.m., Eastern Time.
Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: 877-974-0453, 416-644-3431, or 514-227-8860. A replay of the webcast will also be available on the Company's website for a period of 30 days.
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.
Related Categories
Press ReleasesStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
